Ultragenyx Pharmaceutical Inc. Share Price
Equities
RARE
US90400D1081
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.24 USD | +0.89% | +4.41% | -7.49% |
Sales 2024 * | 515M 42.91B | Sales 2025 * | 630M 52.51B | Capitalization | 3.64B 304B |
---|---|---|---|---|---|
Net income 2024 * | -532M -44.36B | Net income 2025 * | -460M -38.35B | EV / Sales 2024 * | 6.43 x |
Net cash position 2024 * | 334M 27.89B | Net cash position 2025 * | 298M 24.87B | EV / Sales 2025 * | 5.31 x |
P/E ratio 2024 * |
-6.84
x | P/E ratio 2025 * |
-8.46
x | Employees | 1,276 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.88% |
Latest transcript on Ultragenyx Pharmaceutical Inc.
1 day | +0.89% | ||
1 week | +4.41% | ||
Current month | -5.25% | ||
1 month | -2.68% | ||
3 months | -1.62% | ||
6 months | +28.19% | ||
Current year | -7.49% |
Managers | Title | Age | Since |
---|---|---|---|
Emil Kakkis
FOU | Founder | 63 | 22/10/22 |
Howard Horn
DFI | Director of Finance/CFO | 47 | 16/23/16 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | - | 01/17/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deborah Dunsire
BRD | Director/Board Member | 61 | 06/17/06 |
Emil Kakkis
FOU | Founder | 63 | 22/10/22 |
Daniel Welch
CHM | Chairman | 66 | 08/15/08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.21% | 1 M€ | 0.00% | - | |
0.82% | 4 M€ | +20.15% | ||
0.43% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 44.24 | +0.89% | 450,422 |
25/24/25 | 43.85 | -0.97% | 470,806 |
24/24/24 | 44.28 | -1.84% | 670,632 |
23/24/23 | 45.11 | +3.25% | 836,696 |
22/24/22 | 43.69 | +3.12% | 592,387 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.49% | 3.64B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RARE Stock